Stay updated with breaking news from Mark Altmeyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed's first-in-class, non-opioid investigational drug for the treatment of
NIH, through the Helping to End Addiction Long-term Initiative, to sponsor the Phase 2b SERENDIPITY-1 study, evaluating NRD.E1 in patients with painful diabetic peripheral neuropathy (PDPN)
Press release content from Business Wire. The AP news staff was not involved in its creation.
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults* January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Arvelle Therapeutics, an emerging biopharmaceutica...
Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments - Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million - Angelini Pharma will become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments - Opening direct affiliates in France, UK, Nordics and Switzerland by 2022 News provided by Share this article ROME, Jan. 14, 2021 /PRNewswire/ -- Angelin...